No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
98% dehydrated alcohol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
[1] 298 |
2 |
A04ad10 |
- |
- |
- |
- |
[1] 298 |
3 |
Acetate |
Acetate |
- |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
4 |
Acetyl-l-carnitine |
Acetylcarnitine |
- |
- |
- |
[1] 298 |
5 |
Acetyl-l-carnitine 1000mg 2x per day for 3 months |
Acetylcarnitine |
- |
- |
- |
[1] 298 |
6 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
[14] 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
7 |
Alanine |
L-alanine |
D00012 |
- |
- |
[3] 13, 298, 299 |
8 |
Alcohol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
[4] 13, 58, 279, 298 |
9 |
Alpha 1-antitrypsin |
Alpha-1-proteinase inhibitor |
- |
- |
- |
[1] 298 |
10 |
Amino acids |
Amino acids |
- |
- |
- |
[4] 70, 90, 240, 298 |
11 |
Amlodipine |
Amlodipine |
D00615, D02914, D07450 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[4] 51, 65, 67, 298 |
12 |
Amlodipine (drug) |
Amlodipine |
D00615, D02914, D07450 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 298 |
13 |
Analgesics |
- |
- |
- |
- |
[1] 298 |
14 |
Antioxidant plus pregabalin |
Pregabalin |
D02716 |
[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
[1] 298 |
15 |
Antioxidants |
- |
- |
- |
- |
[4] 90, 298, 301, 310 |
16 |
Antox (vers.)1.2 |
- |
- |
- |
- |
[1] 298 |
17 |
Antox version 1.2 |
- |
- |
- |
- |
[1] 298 |
18 |
Autologous mesenchymal stromal cell |
- |
- |
- |
- |
[2] 96, 298 |
19 |
Benzoyl-l-tyrosyl-[1-13c]alanine (bz-tyr-ala) |
L-alanine |
D00012 |
- |
- |
[1] 298 |
20 |
Bupivacaine |
Bupivacaine |
D01450, D07552 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[7] 46, 53, 70, 96, 168, 226, 298 |
21 |
Bupivacaine & triamcinolone acetonide |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 298 |
22 |
Bupivicaine alone |
- |
- |
- |
- |
[1] 298 |
23 |
Calcium |
Calcium |
- |
- |
- |
[24] 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
24 |
Calcium, dietary |
Calcium |
- |
- |
- |
[1] 298 |
25 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
[7] 6, 46, 85, 86, 96, 97, 298 |
26 |
Carbon monoxide |
Carbon monoxide |
D09706 |
- |
- |
[3] 85, 86, 298 |
27 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[8] 5, 13, 58, 96, 97, 265, 298, 316 |
28 |
Cholecalciferol |
Cholecalciferol |
D00188 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[9] 13, 19, 34, 46, 49, 96, 97, 298, 299 |
29 |
Creon |
Pancrelipase amylase |
- |
- |
- |
[2] 298, 299 |
30 |
Creon 10000 |
Pancrelipase amylase |
- |
- |
- |
[2] 298, 299 |
31 |
Creon 25000 |
Pancrelipase amylase |
- |
- |
- |
[2] 298, 299 |
32 |
Creon36™ |
- |
- |
- |
- |
[1] 298 |
33 |
Diazepam |
Diazepam |
D00293 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[3] 46, 155, 298 |
34 |
Dronabinol |
Dronabinol |
D00306 |
[2] CNR1, CNR2 |
[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
[5] 2, 13, 46, 271, 298 |
35 |
Ensure surgical |
- |
- |
- |
- |
[1] 298 |
36 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[6] 6, 46, 86, 98, 298, 299 |
37 |
Etanercept |
Etanercept |
D00742 |
[2] LTA, TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[14] 15, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
38 |
Eur-1008 (apt-1008) high dose |
- |
- |
- |
- |
[1] 298 |
39 |
Eur-1008 (apt-1008) low dose |
- |
- |
- |
- |
[1] 298 |
40 |
Eur-1066-a |
- |
- |
- |
- |
[1] 298 |
41 |
Eur-1066-b |
- |
- |
- |
- |
[1] 298 |
42 |
Fluimucil*20cpr eff 600mg |
- |
- |
- |
- |
[2] 94, 298 |
43 |
Gabapentin |
Gabapentin |
D00332 |
[5] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
[9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
[5] 6, 13, 19, 70, 298 |
44 |
Gabapentin prescriptions |
Gabapentin |
D00332 |
[5] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
[9] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
[1] 298 |
45 |
Helopanflat mono® |
- |
- |
- |
- |
[1] 298 |
46 |
Hemoglobin |
Hemoglobin |
- |
- |
- |
[1] 298 |
47 |
Human secretin |
Secretin human |
- |
- |
- |
[1] 298 |
48 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
[18] 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
49 |
Intra plexus triamcinolone and bupivicaine injection |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 298 |
50 |
Kreon 25000 |
- |
- |
- |
- |
[2] 298, 299 |
51 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[6] 13, 96, 97, 265, 298, 316 |
52 |
Lanreotide |
Lanreotide |
D04666 |
- |
- |
[4] 67, 73, 85, 298 |
53 |
Lanreotide acetate |
Lanreotide |
D04666 |
- |
- |
[3] 73, 85, 298 |
54 |
Lipase |
- |
- |
- |
- |
[1] 298 |
55 |
Liprotamase |
- |
- |
- |
- |
[2] 298, 299 |
56 |
Lyrica |
Pregabalin |
D02716 |
[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
[1] 298 |
57 |
Lyrica® |
- |
- |
- |
- |
[1] 298 |
58 |
Magnesium |
Magnesium |
- |
- |
- |
[15] 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
59 |
Mezym f |
- |
- |
- |
- |
[1] 298 |
60 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[10] 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
61 |
Monitor |
Methamidophos |
- |
- |
- |
[12] 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
62 |
Ms1819 |
Ms1819 |
- |
- |
- |
[2] 298, 299 |
63 |
Ms1819-sd |
Ms1819 |
- |
- |
- |
[2] 298, 299 |
64 |
Multienzymes (lipase, protease etc.) |
- |
- |
- |
- |
[1] 298 |
65 |
Namisol |
- |
- |
- |
- |
[2] 13, 298 |
66 |
Nexium (esomeprazole magnesium) |
Esomeprazole |
D01984, D04056, D07917, D09339 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[1] 298 |
67 |
Ni-03 |
- |
- |
- |
- |
[1] 298 |
68 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[15] 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
69 |
Oxycodone |
Oxycodone |
D03783, D05312, D05462 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[7] 6, 13, 46, 70, 226, 231, 298 |
70 |
Oxycodone depot ”sandoz”, depot tablets |
Oxycodone |
D03783, D05312, D05462 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[1] 298 |
71 |
Oxycodone hydrochloride |
Oxycodone |
D03783, D05312, D05462 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[3] 70, 226, 298 |
72 |
Oxycodonhydrochlorid ”lannacher”, depot tablets |
- |
- |
- |
- |
[1] 298 |
73 |
Oxynorm |
- |
- |
- |
- |
[1] 298 |
74 |
Pancreatic enzymes |
- |
- |
- |
- |
[1] 298 |
75 |
Pancreatin |
Pancrelipase |
D05349 |
- |
- |
[2] 298, 299 |
76 |
Pancrelipase |
Pancrelipase |
D05349 |
- |
- |
[4] 96, 97, 298, 299 |
77 |
Pancrelipase delayed release capsule |
Pancrelipase |
D05349 |
- |
- |
[2] 298, 299 |
78 |
Pancrelipase/pancreas powder |
Pancrelipase |
D05349 |
- |
- |
[2] 298, 299 |
79 |
Panzytrat |
Pancrelipase |
D05349 |
- |
- |
[2] 298, 299 |
80 |
Panzytrat 25.000 |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
81 |
Panzytrat 25.000 fip-e units of lipase |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
82 |
Pentoxifylline |
Pentoxifylline |
D00501 |
- |
- |
[10] 26, 56, 84, 93, 96, 113, 220, 222, 296, 298 |
83 |
Perflubutane |
Perflubutane |
D05440 |
- |
- |
[2] 298, 300 |
84 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
85 |
Pl 00512/0150 |
- |
- |
- |
- |
[1] 298 |
86 |
Pregabalin |
Pregabalin |
D02716 |
[4] CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
[7] Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
[5] 13, 36, 46, 70, 298 |
87 |
Prolastin-c |
Alpha-1-proteinase inhibitor |
- |
- |
- |
[2] 231, 298 |
88 |
Proton pump inhibitor (ppi) |
- |
- |
- |
- |
[1] 298 |
89 |
Recombinant microbial lipase |
- |
- |
- |
- |
[1] 298 |
90 |
Regn475/sar164877 |
- |
- |
- |
- |
[1] 298 |
91 |
Reparixin |
Reparixin |
D08984 |
[2] CXCR1, CXCR2 |
[7] Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, Human cytomegalovirus infection, Phospholipase D signaling pathway, Viral protein interaction with cytokine and cytokine receptor |
[2] 298, 299 |
92 |
Rg1068 (synthetic human secretin) |
Secretin human |
- |
- |
- |
[1] 298 |
93 |
Rvg 13760 |
- |
- |
- |
- |
[1] 298 |
94 |
S-ketamin |
- |
- |
- |
- |
[1] 298 |
95 |
Sa-001 |
- |
- |
- |
- |
[1] 298 |
96 |
Secretin |
Secretin human |
- |
- |
- |
[1] 298 |
97 |
Simvastatin |
Simvastatin |
D00434 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
98 |
Slv339 |
- |
- |
- |
- |
[1] 298 |
99 |
Somatuline autogel 90 mg |
Lanreotide |
D04666 |
- |
- |
[1] 298 |
100 |
Soy bread |
- |
- |
- |
- |
[1] 298 |
101 |
Synthetic human secretin |
Secretin human |
- |
- |
- |
[1] 298 |
102 |
Tanezumab |
Tanezumab |
D09387 |
[1] NGF |
[8] Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
[2] 226, 298 |
103 |
Tetrahydro-6,6,9-tri methyl-3-penthyl-6 h-dibenzo[ b,d ]pyran-1-ol |
- |
- |
- |
- |
[1] 298 |
104 |
Tetrahydrocannabinol |
Dronabinol |
D00306 |
[2] CNR1, CNR2 |
[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
[2] 13, 298 |
105 |
Thalidomide |
Thalidomide |
D00754 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
106 |
Triamcinolone |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[8] 35, 46, 56, 70, 90, 96, 226, 298 |
107 |
Viokase |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
108 |
Viokase 16 |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
109 |
Viokase 16 (pancrelipase) + nexium |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
110 |
Viokase® 16 |
Pancrelipase |
D05349 |
- |
- |
[1] 298 |
111 |
Vitamin d |
Vitamin d |
- |
- |
- |
[18] 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
112 |
Vitamin d 100ug |
Vitamin d |
- |
- |
- |
[1] 298 |
113 |
Vitamin d 10ug |
Vitamin d |
- |
- |
- |
[1] 298 |
114 |
Yarrowia lipolytica lipase |
- |
- |
- |
- |
[1] 298 |
115 |
Zenpep |
Pancrelipase amylase |
- |
- |
- |
[2] 298, 299 |
116 |
Zentase |
- |
- |
- |
- |
[1] 298 |